For instance, TAMs can switch from pro-tumoral to anti-tumoral status and cooperate with TILs leading to reduced tumor burden after STING/Type 1 IFN activation or inhibition of Class IIa HDAC or Clever-1 [42–44]. This evidence concerns the gene STING1 and neoplasm.